{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:25:20Z","timestamp":1765887920943,"version":"3.44.0"},"reference-count":35,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2017,10]]},"abstract":"<jats:p>Proton pump inhibitors (PPIs) are widely prescribed and many people remain on them for years. In some, there may be good justification for long-term use; for example, in those with oesophageal stricture, Barrett\u2019s oesophagus or a history of a bleeding gastrointestinal ulcer, or to provide gastroprotection in those at high risk of gastrointestinal complications from taking NSAIDs. However, PPIs are often not used in line with clinical guidelines.<jats:sup>1,2<\/jats:sup> In addition, there are concerns that many people take them for long periods to manage less serious conditions (e.g. indigestion) and may prefer taking them to addressing factors such as diet, obesity or alcohol that may be contributing to their symptoms. Although PPIs are well-tolerated, there is increasing evidence that they may be associated with a range of long-term adverse effects. Here, we review the safety of PPIs and consider whether long-term prescribing needs to be reassessed.<\/jats:p>","DOI":"10.1136\/dtb.2017.10.0541","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T19:25:09Z","timestamp":1507749909000},"page":"117-120","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Prescribing PPIs"],"prefix":"10.1136","volume":"55","member":"239","published-online":{"date-parts":[[2017,10,11]]},"reference":[{"key":"2025082722403511000_55.10.117.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39406.449456.BE"},{"key":"2025082722403511000_55.10.117.2","first-page":"354","article-title":"Deprescribing proton pump inhibitors: evidence-based clinical practice guideline","volume":"63","author":"Farrell","year":"2017","journal-title":"Can Fam Physician"},{"key":"2025082722403511000_55.10.117.3","unstructured":"All Wales Medicines Strategy Group, 2017. National prescribing indicators 2017-2018 for Wales [online]. Available: http:\/\/www.awmsg.org\/docs\/awmsg\/medman\/National%20Prescribing%20Indicators%202017-2018.pdf [Accessed 20 September 2017]."},{"key":"2025082722403511000_55.10.117.4","unstructured":"Open Prescribing, 2017. 1.3.5: proton pump inhibitors [online]. Available: https:\/\/openprescribing.net\/bnf\/010305\/ [Accessed 20 September 2017]."},{"key":"2025082722403511000_55.10.117.5","unstructured":"Joint Formulary Committee. British National Formulary. Edition 73. London: BMJ Group and Pharmaceutical Press, March 2017."},{"key":"2025082722403511000_55.10.117.6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"Vaezi","year":"2017","journal-title":"Gastroenterol"},{"key":"2025082722403511000_55.10.117.7","unstructured":"Welsh Medicines Resource Centre, 2015. Proton pump inhibitors [online]. Available https:\/\/www.wemerec.org\/Documents\/Bulletins\/PPIBulletinOnline.pdf [Accessed 20 September 2017]."},{"key":"2025082722403511000_55.10.117.8","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.179"},{"key":"2025082722403511000_55.10.117.9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050836"},{"key":"2025082722403511000_55.10.117.10","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.108"},{"key":"2025082722403511000_55.10.117.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2011.09.030"},{"key":"2025082722403511000_55.10.117.12","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2010.73"},{"key":"2025082722403511000_55.10.117.13","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.42"},{"key":"2025082722403511000_55.10.117.14","unstructured":"Public Health England, 2013. Updated guidance on the management and treatment of Clostridium difficile infection [online]. Available: www.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/321891\/Clostridium_difficile_management_and_treatment.pdf [Accessed 20 September 2017]."},{"issue":"9","key":"2025082722403511000_55.10.117.15","first-page":"A2","article-title":"Proton pump inhibitors in long term use: recent epidemiological evidence of increased risk of fracture","volume":"5","author":"Medicines and Healthcare products Regulatory Agency","year":"2012","journal-title":"Drug Safety Update"},{"key":"2025082722403511000_55.10.117.16","doi-asserted-by":"publisher","DOI":"10.1370\/afm.1243"},{"key":"2025082722403511000_55.10.117.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2010.12.015"},{"key":"2025082722403511000_55.10.117.18","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","article-title":"Proton-pump inhibitors and risk of fractures: an update meta-analysis","volume":"27","author":"Zhou","year":"2016","journal-title":"Osteoporos Int"},{"key":"2025082722403511000_55.10.117.19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e372"},{"issue":"9","key":"2025082722403511000_55.10.117.20","first-page":"A1","article-title":"Proton pump inhibitors in long-term use: reports of hypomagnesaemia","volume":"5","author":"Medicines and Healthcare products Regulatory Agency","year":"2012","journal-title":"Drug Safety Update"},{"key":"2025082722403511000_55.10.117.21","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2013.1.0169"},{"key":"2025082722403511000_55.10.117.22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.gastro.2017.01.031","article-title":"The risks and benefits of long-term use of proton pump inhibitors: expert review and best practice advice from the American Gastroenterological Association","volume":"152","author":"Freedberg","year":"2017","journal-title":"Gastroenterol"},{"key":"2025082722403511000_55.10.117.23","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2013.280490","article-title":"Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency","volume":"310","author":"Lam","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"2025082722403511000_55.10.117.24","first-page":"1","article-title":"Proton pump inhibitors: very low risk of subacute cutaneous lupus erythematosus","volume":"9","author":"Medicines and Healthcare products Regulatory Agency","year":"2015","journal-title":"Drug Safety Update"},{"key":"2025082722403511000_55.10.117.25","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12069"},{"key":"2025082722403511000_55.10.117.26","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2013-304738"},{"key":"2025082722403511000_55.10.117.27","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.i5813","article-title":"Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study","volume":"355","author":"Othman","year":"2016","journal-title":"BMJ"},{"key":"2025082722403511000_55.10.117.28","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamaneurol.2015.4791","article-title":"Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis","volume":"73","author":"Gomm","year":"2016","journal-title":"JAMA Neurol"},{"key":"2025082722403511000_55.10.117.29","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.14956"},{"key":"2025082722403511000_55.10.117.30","doi-asserted-by":"publisher","DOI":"10.9778\/cmajo.20140074"},{"key":"2025082722403511000_55.10.117.31","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.7193"},{"key":"2025082722403511000_55.10.117.32","unstructured":"European Medicines Agency, 2017. Pharmacovigilance Risk Assessment Committee (PRAC): Minutes of the meeting on 9-12 January 2017 [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Minutes\/2017\/04\/WC500225782.pdf [Accessed 20 September 2017]"},{"issue":"9","key":"2025082722403511000_55.10.117.33","first-page":"4","article-title":"Clopidogrel and proton pump inhibitors: interaction \u2013 updated advice","volume":"3","author":"Medicines and Healthcare products Regulatory Agency","year":"2010","journal-title":"Drug Safety Update"},{"key":"2025082722403511000_55.10.117.34","doi-asserted-by":"crossref","first-page":"515","DOI":"10.3109\/00365521.2012.746395","article-title":"Systematic review: symptoms of rebound acid hypersecretion following proton pump inhibitor treatment","volume":"48","author":"L\u00f8drup","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"2025082722403511000_55.10.117.35","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmu050"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2017.10.0541","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:40:56Z","timestamp":1756359656000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2017.10.0541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2017,10,11]]},"published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.1136\/dtb.2017.10.0541"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2017.10.0541","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}